MLN-9708 | B2195

MLN-9708 is a prodrug of Ixazomib citrate (MLN-2238). MLN-9708 is an orally bioavailable next-generation proteasome inhibitor (PI) with potential potent anticancer activity in both hematologic and solid tumor xenograft models with better pharmacokinetic and pharmacodynamic features than PS-341 (Cat. No. 1846).

MLN-9708 is a prodrug of Ixazomib citrate (MLN-2238). MLN-9708 is an orally bioavailable next-generation proteasome inhibitor (PI) with potential potent anticancer activity in both hematologic and solid tumor xenograft models with better pharmacokinetic and pharmacodynamic features than PS-341 (Cat. No. 1846).

B2195 | MLN-9708 DataSheet

Alternate Name/Synonyms: 4-(carboxymethyl)-2-((R)-1-(2-(2,5-dichlorobenzamido)acetamido)-3-methylbutyl)-6-oxo-1,3,2-dioxaborinane-4-carboxylic acid; ixazomib

Appearance: Off-white solid

Formulation: N/A

CAS Number: 1239908-20-3

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₂₀H₂₃BCl₂N₂O₉

Molecular Weight: 517.12

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: A next-generation proteasome inhibitor (PI)

MDL Number: N/A

PubChem CID: 56844015

SMILES: B1(OC(=O)C(O1)(CC(=O)O)CC(=O)O)C(CC(C)C)NC(=O)CNC(=O)C2=C(C=CC(=C2)Cl)Cl

InChi: InChI=1S/C20H23BCl2N2O9/c1-10(2)5-14(21-33-19(32)20(34-21,7-16(27)28)8-17(29)30)25-15(26)9-24-18(31)12-6-11(22)3-4-13(12)23/h3-4,6,10,14H,5,7-9H2,1-2H3,(H,24,31)(H,25,26)(H,27,28)(H,29,30)/t14-/m0/s1

InChi Key: MBOMYENWWXQSNW-AWEZNQCLSA-N